Neurocrine Biosciences
NBIX
#1497
Rank
ยฃ10.85 B
Marketcap
ยฃ106.80
Share price
-1.55%
Change (1 day)
4.48%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): ยฃ5.28

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is ยฃ5.33. In 2025 the company made an earnings per share (EPS) of ยฃ3.64 an increase over its 2024 EPS that were of ยฃ2.56.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)ยฃ5.2844.87%
2025ยฃ3.6442.6%
2024ยฃ2.5633.07%
2023ยฃ1.9257.76%
2022ยฃ1.2269.47%
2021ยฃ0.72-78.21%
2020ยฃ3.30990%
2019ยฃ0.3081.82%
2018ยฃ0.17-113.5%
2017-ยฃ1.230.62%
2016-ยฃ1.2257.28%
2015-ยฃ0.7825.61%
2014-ยฃ0.6218.84%
2013-ยฃ0.52-1085.71%
2012ยฃ0.05293

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
ยฃ0.57-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
ยฃ2.70-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
ยฃ22.60 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
ยฃ0.57-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-ยฃ1.53-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
ยฃ3.65-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-ยฃ5.71-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
ยฃ1.42-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK